Request for Proposal
Status: RFP is Closed

Technologies linking Cardiovascular Risks and Type II Diabetes within the Patient Community

Request Number
Due Date
Oct 20, 2018
Program Manager


Flexible Partnering Opportunities: Partnerships, Licensing, Collaborative Development, Development Projects


Phase 1 – Review of Proposals by October 2018

Phase 2 – Collaborations starting December 2018


All financial terms are to be negotiated depending on the current status of the technology

For questions and comments, you are welcome to contact the Ninesigma Programme Manager, Oliver Worsfold.



RFP was closed on
Oct 2018

RFP Title


Technologies linking Cardiovascular Risks and Type II Diabetes within the Patient Community
RFP Description

NineSigma, representing a global pharmaceutical company, invites proposals for novel ways to make cardiovascular risks tangible to physicians and (diabetes Type II) patients. For example, to increase awareness of cardiovascular risks and enable diabetes patients to better grasp their elevated CV risks, as a starting point for behavioral changes and increased self-empowerment to better manage their disease.


Diabetes mellitus is a chronic condition that occurs when the body can’t produce enough or effectively use insulin. Compared with individuals without diabetes, patients with Type 2 diabetes mellitus (T2D) have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular diseases.  

T2D is associated with cardiovascular (CV) risk factors, such as dyslipidemia, hypertension, hyperglycemia, obesity, and increased oxidative stress. CV disease (CVD) is the leading cause of mortality in patients with diabetes, accounting for ~50% of deaths and reducing the life expectancy of a 60-year-old patient with T2D by an average of 12 years compared with the general population. Indeed, patients with T2D are two to four times more likely to have CVD than the general population.

In contrast, according to a previous study, 86% of the people with diabetes do not consider CVD to be a serious complication of diabetes; they are more likely to be aware of complications such as blindness or amputation, rather than heart disease, heart attack or stroke. So far, traditional awareness campaigns, fact sheets and educational materials have shown only limited effects in making the severity of cardiovascular risks for an individual with T2D tangible

Key Success Criteria

Our client is seeking digital or mobile solutions that:

  • Involve novel approaches to make the link between diabetes and the patient’s heart
  • Train and entertain diabetes patients about their cardiovascular risks
    • Fit into their daily life
    • Create a sense of urgency and motivate patients to actively address cardiovascular risks, e.g. by consulting their physician
    • Can achieve a fast, high and durable penetration of the Type II diabetes patient community
  • Also involve the HCP and create a positive feedback loop between the patient and HCP
Possible Approaches

Open to all approaches that meet some or all of the described requirements including the following:

  • Diagnostic assays, i.e. assays for high usage with clear link to CVD
  • Digital solutions shown to work for other disease areas
  • Patient awareness programmes approved with HCP
  • “Gamifying” mobile solutions to engage the diabetes community
Items to be Submitted

Appropriate responses will include only non-confidential information:

  • Overview of proposed solution
  • Status of technology and obstacles to be overcome (if required)
  • Brief overview of the respondent(s)
  • Overview of respondent(s) organization(s)
  • A description of your / your organisations experience with digital / mobile solutions to achieve the success criteria
  • A description of your / your organisations experience with Type II diabetes patients and/or cardiovascular diseases  or similar programs in other diseases (if any)
  • IP ownership / policy / freedom to operate
Preferred Collaboration Types
Area of Interest